Format
Sort by

Send to

Choose Destination

Search results

Items: 2

1.

Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial.

Abraham S, Juel HB, Bang P, Cheeseman HM, Dohn RB, Cole T, Kristiansen MP, Korsholm KS, Lewis D, Olsen AW, McFarlane LR, Day S, Knudsen S, Moen K, Ruhwald M, Kromann I, Andersen P, Shattock RJ, Follmann F.

Lancet Infect Dis. 2019 Aug 12. pii: S1473-3099(19)30279-8. doi: 10.1016/S1473-3099(19)30279-8. [Epub ahead of print]

PMID:
31416692
2.

Design of artificial red blood cells using polymeric hydrogel microcapsules: hydrogel stability improvement and polymer selection.

Zhang W, Bissen MJ, Savela ES, Clausen JN, Fredricks SJ, Guo X, Paquin ZR, Dohn RP, Pavelich IJ, Polovchak AL, Wedemeyer MJ, Shilling BE, Dufner EN, O'Donnell AC, Rubio G, Readnour LR, Brown TF, Lee JC, Kaltchev MG, Chen J, Tritt CS.

Int J Artif Organs. 2016 Oct 1;39(10):518-523. doi: 10.5301/ijao.5000532. Epub 2016 Nov 16.

PMID:
27886350

Supplemental Content

Support Center